In this episode of "In the Interim...", Dr. Scott Berry investigates the practical meaning of fairness by connecting a controversial World Cup soccer ruling to foundational questions in clinical trial statistics.

On the latest episode of "In the Interim...", Dr. Scott Berry and Dr. Kert Viele deliver a focused, technical analysis of statistical bias when stopping trials early.

In today's blog, Dr. Kert Viele breaks down the most crucial updates of the draft guidance on "Master Protocols for Drug and Biological Product Development," specifically focusing on the new details surrounding basket trials, control group requirements, and the heavy integration of the FDA's draft Bayesian guidance.

On the latest episode of "In the Interim…", Dr. Scott Berry provides an empirical examination of two recent JAMA trials: TRACK (low-dose rivaroxaban in advanced kidney disease) and VICTORY (IV vitamin C in severe burn injury).

On the latest episode of "In the Interim…", Dr. Scott Berry provides an empirical examination of two recent JAMA trials: TRACK (low-dose rivaroxaban in advanced kidney disease) and VICTORY (IV vitamin C in severe burn injury).

In this week's blog, Dr. Kert Viele discusses his thoughts on the RAR literature and the current state of RAR in practical clinical trials. He focuses on general principles that have emerged in the literature, the nuts and bolts of constructing and tuning RAR designs, and operational issues.